---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036162"
form_type: "8-K"
ticker: null
cik: "0001923840"
company_name: "Third Harmonic Bio, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T08:07:54.664503+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Third Harmonic Bio reports $269.1M cash, files IND for THB335, Q4 net loss narrows

## Summary
- Cash and equivalents $269.1M as of Dec 31, 2023; expected to fund operations through at least 2026.
- Net loss for Q4 2023 was $6.8M versus $11.5M in Q4 2022; full-year net loss $30.8M.
- R&D expenses decreased to $5.9M in Q4 2023 from $9.3M year-over-year.
- U.S. IND filed for THB335, a potential first-in-class oral KIT inhibitor for chronic spontaneous urticaria.
- Phase 1 SAD/14-day MAD study in healthy volunteers anticipated to start in Q2 2024.

## SEC filing metadata
- accession: 0000950170-24-036162
- form_type: 8-K
- cik: 0001923840
- company_name: Third Harmonic Bio, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1923840/000095017024036162/0000950170-24-036162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1923840/000095017024036162/thrd-20240326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036162
- JSON: https://secwatch.observer/filing/0000950170-24-036162.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036162.txt

## Key facts
- Earnings Releases
  Third Harmonic Bio, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the three months ended December 31, 2023 decreased to $6.8 million from a net loss of $11.5 million for the.
  - Period: fourth quarter and full year ended December 31, 2023
  - Net income: Net loss for the three months ended December 31, 2023 decreased to $6.8 million from a net loss of $11.5 million for the
  - Result: reported results
  source text: Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1923840/000095017024036162/0000950170-24-036162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.